Terril Brothers Inc. Acquires 6,850 Shares of Solventum Corporation $SOLV

Terril Brothers Inc. raised its holdings in shares of Solventum Corporation (NYSE:SOLV) by 2.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 271,851 shares of the company’s stock after purchasing an additional 6,850 shares during the period. Solventum accounts for approximately 5.6% of Terril Brothers Inc.’s investment portfolio, making the stock its 7th biggest holding. Terril Brothers Inc.’s holdings in Solventum were worth $21,541,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of Solventum by 5.3% during the third quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock worth $1,249,847,000 after purchasing an additional 867,837 shares in the last quarter. Independent Franchise Partners LLP increased its position in shares of Solventum by 27.2% during the third quarter. Independent Franchise Partners LLP now owns 12,899,240 shares of the company’s stock worth $941,645,000 after purchasing an additional 2,758,174 shares in the last quarter. State Street Corp increased its position in shares of Solventum by 1.8% during the third quarter. State Street Corp now owns 6,220,271 shares of the company’s stock worth $454,080,000 after purchasing an additional 112,261 shares in the last quarter. Davis Selected Advisers increased its position in shares of Solventum by 12.7% during the fourth quarter. Davis Selected Advisers now owns 6,220,072 shares of the company’s stock worth $492,880,000 after purchasing an additional 702,461 shares in the last quarter. Finally, Boston Partners increased its position in shares of Solventum by 26.1% during the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock worth $338,006,000 after purchasing an additional 959,543 shares in the last quarter.

Analyst Ratings Changes

A number of brokerages have recently issued reports on SOLV. Stifel Nicolaus reduced their price target on Solventum from $105.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Weiss Ratings reissued a “hold (c)” rating on shares of Solventum in a research report on Tuesday, January 27th. Wells Fargo & Company cut their target price on Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research report on Wednesday, May 6th. Rothschild & Co Redburn assumed coverage on Solventum in a research report on Tuesday, March 24th. They issued a “sell” rating and a $60.00 target price on the stock. Finally, UBS Group downgraded Solventum from a “buy” rating to a “neutral” rating and set a $50.00 target price on the stock. in a research report on Thursday, May 14th. Eight equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $84.25.

Solventum Price Performance

NYSE SOLV opened at $76.23 on Wednesday. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75. The stock’s fifty day moving average price is $69.09 and its 200 day moving average price is $74.94. Solventum Corporation has a 1 year low of $62.38 and a 1 year high of $88.20. The company has a market cap of $13.20 billion, a price-to-earnings ratio of 9.34, a PEG ratio of 1.19 and a beta of 0.59.

Solventum (NYSE:SOLV) last released its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.35 by $0.13. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The firm had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same period in the prior year, the firm earned $1.34 EPS. The firm’s revenue was down 3.0% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, equities research analysts forecast that Solventum Corporation will post 6.57 earnings per share for the current year.

Insider Activity

In related news, Director Amy Mcbride Wendell purchased 1,475 shares of the business’s stock in a transaction on Tuesday, March 10th. The shares were bought at an average cost of $68.03 per share, with a total value of $100,344.25. Following the transaction, the director owned 5,039 shares of the company’s stock, valued at approximately $342,803.17. This trade represents a 41.39% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.24% of the stock is currently owned by insiders.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.